Neuropathy

Miami, FL

47 Neuropathy Trials near Miami, FL

Power is an online platform that helps thousands of Neuropathy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7. All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be open label and will enroll participants at increasing dose levels of BXQ-350 in order to determine the Stage 2 dose. Stage 2 will be blinded; participants will receive BXQ-350 at the established Stage 1 dose or placebo.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

195 Participants Needed

The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3

300 Participants Needed

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1100 Participants Needed

This trial is testing a new drug called LY3556050 to see if it can help reduce nerve pain in people with diabetes. The study will last several months and will compare the effects of LY3556050 to another treatment. The goal is to determine if LY3556050 is safe and effective for treating diabetic nerve pain.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

410 Participants Needed

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

300 Participants Needed

This trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

384 Participants Needed

The study is a dose-escalation study, phase 1. The objective of this proposed clinical trial is to evaluate the safety of mitochondrially targeted ND4 gene therapy with the adeno-associated viral vector in appropriate LHON patients.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:15+

28 Participants Needed

This trial is testing different treatments for chronic pain in patients with knee osteoarthritis, chronic low back pain, and diabetic nerve pain. It aims to find effective ways to reduce their chronic pain.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

10000 Participants Needed

This phase II trial tests the safety, side effects, and best dose of monosialotetrahexosylganglioside (GM1) and whether it works in reducing or preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) who are receiving treatment with paclitaxel. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Exposure to chemotherapy drugs like paclitaxel may cause a side effect called CIPN, which is a condition of weakness, numbness, and pain from nerve damage (usually in the hands and feet). GM1 is a part of the body's natural system that insulates nerves and helps to protect nerves from damage. Giving GM1 may help reduce or prevent CIPN in breast cancer patients receiving treatment with paclitaxel.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

98 Participants Needed

This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

134 Participants Needed

This study is designed to assess the efficacy and safety of AT-007 treatment in patients with SORD Deficiency. This randomized, double-blind study will assess the effect of AT-007 compared to Placebo in SORD Deficiency in patients for up to 24 months.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:18 - 55

56 Participants Needed

This trial is testing the safety and effectiveness of acoramidis in people with a heart condition called ATTR-CM. The drug works by preventing harmful protein clumps in the heart. Participants must have completed a previous study and cannot use other specific treatments during this trial.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

389 Participants Needed

AZD2962 for Cancer

Miami, Florida
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

72 Participants Needed

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female

40 Participants Needed

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

350 Participants Needed

The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy by a suitably qualified and licensed health professional.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22+

32 Participants Needed

This trial is testing a new drug called LX9211 to see if it can reduce nerve pain in people with diabetes. The drug works by blocking pain signals in the nerves. Researchers want to find out if it is more effective than other treatments. A similar drug was previously tested for similar conditions but its development was halted due to safety concerns.

Trial Details

Trial Status:Active Not Recruiting

416 Participants Needed

LY3848575 for Neuropathic Pain

Miami Lakes, Florida
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

450 Participants Needed

This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who have been unable to sufficiently manage their pain.

Trial Details

Trial Status:Active Not Recruiting

145 Participants Needed

The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with suspected Cardiac Amyloidosis. The imaging test that will be used in this study is a Positron Emission Tomography Computed Tomography (PET/CT) scan.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

200 Participants Needed

Why Other Patients Applied

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

Nab-sirolimus for Cancer

Fort Lauderdale, Florida
This trial is testing a new drug on adults and adolescents with certain genetic changes in their tumors. These changes make their cancer hard to treat with standard methods. The drug works by blocking a pathway that helps the cancer grow, aiming to slow down or stop tumor growth. The drug has been studied for its effectiveness and safety in various types of cancer.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:12+

120 Participants Needed

This phase II trial studies whether a prior germline predictor of taxane-induced peripheral neuropathy (TIPN) can help identify a subgroup of patients who are at higher risk of chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer. The study also investigates whether docetaxel maybe work better than paclitaxel with regard to TIPN rate/severity and dose reductions.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female

249 Participants Needed

The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

115 Participants Needed

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

500 Participants Needed

This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

500 Participants Needed

ART0380 for Advanced Cancer

West Palm Beach, Florida
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

502 Participants Needed

Halneuron for Neuropathy

Port Charlotte, Florida
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

200 Participants Needed

To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease. The trial period will comprise a Screening period (up to 35 Days), randomization and a 4-day treatment period, followed by a 12-week follow up period (12 weeks total after initial treatment), and an End-of-Trial/Follow-up visit which will occur at Week 13. This is a study to research the effects of the study drug on neuropathic pain compared placebo.

Trial Details

Trial Status:Recruiting
Age:21+

222 Participants Needed

ACR-2316 for Cancer

Sarasota, Florida
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

90 Participants Needed

DNTH103 for Neuropathy

Bradenton, Florida
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

36 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Neuropathy clinical trials in Miami, FL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Neuropathy clinical trials in Miami, FL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Neuropathy trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL for Neuropathy is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Neuropathy medical study in Miami, FL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Neuropathy clinical trials in Miami, FL?

Most recently, we added AZD2962 for Cancer, ROC-101 for Pulmonary Hypertension and Mobile Health App for Peripheral Neuropathy to the Power online platform.

Does anything really work for neuropathy?

Yes—real results come from tackling neuropathy on two fronts. First, fix the underlying cause whenever possible (tighten blood-sugar control, replace low B-12, adjust thyroid levels, stop a toxic medication, or use immune treatment for disorders like CIDP) because this can slow or even reverse nerve damage. Second, control the discomfort with proven options—prescription pills such as duloxetine or pregabalin/gabapentin, high-dose capsaicin or lidocaine skin patches, plus regular aerobic exercise and physical therapy—which can markedly cut burning, tingling or numbness while the root problem is being addressed.

What triggers neuropathy flare-ups?

A neuropathy “flare” usually happens when already-injured nerves face extra stress. The most common stressors fall into four buckets: 1) metabolic swings such as high or rapidly changing blood sugar or low vitamin B12, 2) lifestyle chemicals like alcohol or smoking, 3) mechanical or environmental insults—tight shoes, prolonged pressure, cold or heat, vibrations—or 4) medicines and illnesses that irritate nerves (certain chemotherapies, infections, thyroid or kidney problems). Tracking your symptoms alongside these factors (e.g., glucose readings, alcohol intake, recent medications, exposures) can help you and your doctor pinpoint personal triggers and plan ways to avoid them.

Is foot neuropathy progressive?

Most kinds of foot neuropathy do tend to worsen over time, especially when the underlying cause—such as poorly controlled diabetes, ongoing alcohol use, or certain chemotherapy drugs—continues to injure the nerves. Progression is not inevitable, though; correcting a vitamin-B12 shortage, improving blood-sugar levels, changing a medication, or simply protecting the feet can slow, stop, and sometimes partly reverse the damage. The takeaway: work with your clinician to pin down the cause early and tackle those risk factors so the condition doesn’t silently advance.

Are eggs bad for neuropathy?

For most people with neuropathy, an egg or two a few times a week is safe and can even help by providing vitamin B12 and choline that nerves need; the exception is if you have an egg allergy or your doctor has asked you to limit cholesterol. Focus on a balanced plate—plenty of vegetables, whole grains, and lean proteins—while monitoring blood sugar, weight, and how your body feels after different foods; if eggs don’t trigger symptoms and your lab numbers stay on target, they aren’t “bad” for your neuropathy.

What is often mistaken for neuropathy?

Several other problems can create numbness, tingling or burning, so neuropathy is often confused with a pinched nerve in the spine (radiculopathy), poor circulation to the legs and feet (peripheral artery disease), widespread pain disorders like fibromyalgia, vitamin B-12 deficiency, restless-leg syndrome, or brain/spinal-cord diseases such as multiple sclerosis. Notice whether symptoms stay in one limb, change with posture or walking, improve when you move, or come with fatigue, vision or wound-healing issues—those patterns can hint at a cause other than nerve damage. Because each condition has different treatments, any persistent or worsening sensation changes should be evaluated by a healthcare professional.

Can nerves regenerate from neuropathy?

Peripheral nerves can regrow, but they do so slowly—about a millimetre a day—so recovery takes months and is most successful when the underlying cause (like diabetes, vitamin B-12 deficiency, or pressure on a nerve) is corrected early. Full return of feeling or strength isn’t guaranteed, yet good blood-sugar control, stopping toxins (alcohol, certain drugs), proper vitamins, and guided exercise greatly improve the odds; nerves in the brain or spinal cord, however, rarely regenerate. In short, ask your doctor to hunt for—and treat—the cause, protect the numb area while healing occurs, and be patient with the gradual progress.

What vitamin is used for neuropathy?

The best-studied “nerve vitamins” are B-vitamins—especially B12 (about 1 mg daily or by injection for deficiency) and the B1 derivative benfotiamine (150–300 mg twice daily)—which small clinical trials show can improve nerve pain and conduction in diabetic or alcoholic neuropathy; vitamin B6 helps only if levels are low and should stay below 100 mg a day to avoid toxicity. Emerging research suggests that correcting low vitamin D (e.g., 1000–2000 IU daily, or higher short courses under medical supervision) may ease diabetic nerve pain, whereas other vitamins or minerals have little proof. Because dosing and causes of neuropathy vary, ask your doctor to measure B12 and vitamin D levels and guide any supplementation.

Is there a walking device for neuropathy?

Yes. Options range from sensory-substitution wearables like Walkasins that vibrate above the ankle to restore lost foot feedback, to functional-electrical-stimulation braces for foot-drop and standard aids such as canes or trekking poles; each targets different neuropathy-related walking problems. A physical therapist or neurologist can test your sensation and balance and let you trial the device type most likely to improve your safety and confidence.

How to stop neuropathy from progressing?

Nerves keep getting damaged only if the thing that is hurting them stays active, so the first step is to have a doctor pin down the exact cause—-for example high blood sugar, low vitamin B-12, alcohol, a pinched nerve, or an immune condition—and treat or remove it right away. At the same time, you can give the nerves their best chance to stabilise by exercising gently every day, eating a nutrient-rich diet, stopping smoking and excess alcohol, and checking your feet and skin daily for injuries you might not feel.

Do magnets help neuropathy?

Current research on magnets for neuropathy is sparse and low-quality; small studies sometimes show pain relief, but just as many find no difference, and no professional guidelines endorse magnetic devices for neuropathic pain. Magnets appear harmless for most people (keep them away from pacemakers), but because evidence of benefit is weak, they should be viewed—at best—as an optional add-on rather than a substitute for proven treatments like good glucose control, exercise, medications (e.g., duloxetine, gabapentin), and foot care.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security